BCWorld Healthcare also made an investment in ReGelTec and the companies are working together to secure regulatory approval in South Korea
Clinical studies show chronic low back pain decreased by more than 80% in 60 patients at three months.
Like fixing a flat on the roadside, a new injectable hydrogel is showing promise as a remedy for worn-down spinal discs -- pumping them back up and relieving chronic back pain.
An experimental formulation of a hydrogel, injected into spinal discs, proved safe and effective in substantially relieving chronic low back pain caused by degenerative disc disease (DDD), according to new research to be presented at the Society of Interventional Radiology Annual Scientific Meeting, in Boston.
“5 Questions With…” is a weekly BioBuzz series where we reach out to interesting people in the BioHealth Capital Region to share a little about themselves, their work, and maybe something completely unrelated.
ReGelTec, Inc., a clinical stage medical device company developing HYDRAFIL™, a percutaneous treatment for chronic low back pain, announced the presentation of Early Feasibility Study (EFS) results by Dr Alfonso Spath at the American Society of Spine Radiology annual meeting that took place February 19-21, 2021.
Dr Doug Beall, medical advisor for ReGelTec, presented at the American Society of Spine Radiology annual meeting on Hydrafil’s development history and the preliminary results of the Early Feasibility Study. Dr Alfonso Spath, Prinicipal Investigator, also presented during the meeting’s scientific session.
By restoring vertebral disc height with an injectable, durable hydrogel, ReGelTec aims to give interventional spine and pain clinicians an effective option for one of the most common causes of low back pain.
ReGelTec, Inc., a medical device company developing a treatment for chronic low back pain, has received breakthrough device designation for its HYRDAFIL System from the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA).
The Breakthrough Device program is intended to help patients receive faster access to technologies that can provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating conditions.
